Healthcare Sector — Q2 FY25 Earnings Overview
3 companies reported. 2 bullish, 1 neutral, 0 bearish.
Average revenue growth: 11.5%
Sector sentiment: bullish
Aggregate revenue: ₹25,904 Cr
Average margin: 23.8%
Company Results
| Company | Revenue | YoY | Margin | Sentiment |
|---|---|---|---|---|
| Sunpharma | ₹13,264 Cr | +10.5% | 29.6% | bullish high |
| Cipla | ₹7,051 Cr | +9% | 26.7% | neutral medium |
| Apollohosp | ₹5,589 Cr | +15% | 15.0% | bullish high |
Key sector risks this quarter
Sunpharma · high
The Leqselvi launch depends on a favorable court ruling on the '335 patent; an unfavorable outcome could delay launch until patent expiry in Dec 2026.
Cipla · highSupply issues at partner site will reduce Q3 lanreotide sales significantly; recovery depends on partner's production ramp-up.
Cipla · highGoa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
Apollohosp · mediumInternational patient revenue from Bangladesh fell 27% in H1, impacting Tamil Nadu volumes. Recovery expected but uncertain.
Apollohosp · mediumQuick commerce players are impacting non-Rx sales, delaying unit economics improvement. Management is rolling out 19-min delivery to counter.